Akorn Overview
- Founded
-
1971
- Status
-
Public
- Employees
-
2,000
- Stock Symbol
-
FDA
- Investments
-
13
Akorn General Information
Description
Akorn Inc is a pharmaceutical company. It is engaged in the development, manufacturing, and marketing of generic and prescription pharmaceuticals. The firm has two segments namely Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment consists of generic and branded prescription pharmaceuticals including sterile ophthalmics, injectables, and inhalants, and non-sterile oral liquids, topicals and nasal sprays whereas the Consumer Health segment consist of animal health and over-the-counter products, both branded and private-label. The company generates a majority of its revenue from the Prescription Pharmaceuticals segment.
Contact Information
Website
www.akorn.com
Formerly Known As
Akorn Ophthalmics
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Distributors (Healthcare)
Drug Discovery
Stock Exchange
DUS
Primary Office
- 1925 West Field Court
- Suite 300
- Lake Forest, IL 60045
- United States
+1 (800) 000-0000
Akorn Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
|---|---|---|---|---|
| Revenue | 663,504 | 682,429 | 694,018 | 841,045 |
| EBITDA | (315,105) | (148,125) | (309,477) | 64,045 |
| Net Income | (358,379) | (226,770) | (401,909) | (24,550) |
| Total Assets | 1,001,764 | 1,288,639 | 1,495,257 | 1,909,511 |
| Total Debt | 885,647 | 867,639 | 820,411 | 815,195 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Akorn Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Akorn Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Akorn Inc is a pharmaceutical company. It is engaged in the development, manufacturing, and marketing of generic and pre
Pharmaceuticals
Lake Forest, IL
2,000
As of 2018
0000000000.
000000
fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia de
000000000000000
Bridgewater, NJ
0000
As of 0000
00.000
000000 - 000
00.000
0000 0
e magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip e
000000000000000
Haifa Bay, Israel
0000
As of 0000
0000
0.000
0000-00-00
00000000000
Add Comparison
Akorn Competitors (25)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals | Formerly PE-Backed | Bridgewater, NJ | 0000 | 00.000 | 000000 - 000 | 00.000 |
| 0000 0000000000000 | Corporate Backed or Acquired | Haifa Bay, Israel | 0000 | 0000 | 00000000000 | |
| 000 00000000000000 | Corporation | Baudette, MN | 000 | 00000 | 000000000 | 00000 |
| 000000000000000 00 | Corporation | Lagos, Nigeria | 00 | |||
| 00000 | Corporation | Mumbai, India | 00000 | 00000000 |
Akorn Patents
Akorn Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10426834-B1 | Methods of sterilizing drugs | Active | 11-Aug-2016 | 000000000 | 0 |
| US-9517269-B1 | Stable pentobarbital formulation | Active | 01-Oct-2013 | 000000000 | |
| US-20090123527-A1 | Method of inducing topical anesthesia and transdermal patch | Abandoned | 24-Jul-2006 | 0000000000 | |
| US-20050249820-A1 | Nutritional supplement for the treatment and prevention of macular degeneration | Abandoned | 04-May-2004 | 000000000 | 0 |
| US-20040186084-A1 | Sterile aqueous composition comprising triamcinolone acetonide, and tonicity-adjusting agents, ph-adjusting agents to provide a ph of between about 5 and 7.5; treating diabetic macular edema and related illness; intravitreal injection | Abandoned | 21-Mar-2003 | A61K31/58 |
Akorn Executive Team (20)
Akorn Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000 000000 00.0 | Self | Founder | 000 0000 |
Akorn Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Akorn Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Akorn Investments & Acquisitions (13)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000000 | 02-Jan-2015 | 0000000000 | 000.00 | Therapeutic Devices | |
| 0000000 | 30-Sep-2014 | 0000000000 | 0000 | Pharmaceuticals | 00000 000 |
| 0000000000 | 12-Aug-2014 | 0000000000 | 00000 | Pharmaceuticals | 00000 000 |
| 00-0000 00000 | 17-Apr-2014 | 0000000000 | 00000 | Pharmaceuticals | 00000 000 |
| BETIMOL | 02-Jan-2014 | Corporate Asset Purchase | 00000 | Buildings and Property | 00000 000 |
Akorn Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 00-0000 000000000 | Pharmaceuticals | Amityville, NY | 0000 |
Akorn Exits (2)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 00000 00000000000 | 11-Aug-2011 | 00000 00000 00 | 000 | Completed |
|
| TheraTears | 03-May-2011 | Merger/Acquisition | 000.00 | Completed |